Should liver metastases of breast cancer be biopsied to improve treatment choice? M. A. Locatelli , G. Curigliano, L. Fumagalli, V. Bagnardi, G. Aurilio, P. Della Vigna, L. Monfardini, S. Giudici, G. Viale, A. Goldhirsch European Institute of Oncology, Milan, Italy Abstract # CRA 1008 Chicago, June 08, 2010
17
Embed
Should liver metastases of breast cancer be biopsied to improve treatment choice?
Abstract # CRA 1008. Should liver metastases of breast cancer be biopsied to improve treatment choice?. M. A. Locatelli , G. Curigliano, L. Fumagalli, V. Bagnardi, G. Aurilio, P. Della Vigna, L. Monfardini, S. Giudici, G. Viale, A. Goldhirsch European Institute of Oncology, Milan, Italy. - PowerPoint PPT Presentation
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Should liver metastases of breast cancer be biopsied to improve treatment choice?
M. A. Locatelli, G. Curigliano, L. Fumagalli, V. Bagnardi, G. Aurilio, P. Della Vigna,
L. Monfardini, S. Giudici, G. Viale, A. Goldhirsch
European Institute of Oncology, Milan, Italy
Abstract # CRA 1008
Chicago, June 08, 2010
Purpose
• To evaluate the rate of discordance of estrogen receptor (ER), progesterone receptor (PgR) and HER2 receptor status between primary breast cancer (BC) and liver metastases
• To evaluate its potential impact on treatment choice
Background
Background
• Nonetheless, currently the acquisition of tissue from metastatic lesions is not recommended as a routine practice
Patients and Methods• Retrospective analysis of 1250 ultrasound
guided liver biopsies performed at IEO from August 1999 to March 2009
• 255/1250 were identified as consecutive female BC
• The occurrence of ER, PgR and HER2 discordance in liver metastasis and primitive BC was evaluated
Patients and Methods: Inclusion Criteria
• Histological diagnosis of primary BC• Unilateral BC with development of liver
metastasis• Recorded expression status of ER, PgR, HER2
in both primary BC and liver metastasis• Any form of therapy: surgical, systemic, and
radio
Patients and Methods: Exclusion Criteria
• Bilateral BC• Male Gender• Ductal carcinoma in situ as initial
diagnosis • Synchronous metastases
Characteristics of patient study populationN (%) Median (range)
Age at diagnosis (years) 45 (26-75)
Triple negative status at primaryYesNoUnknown
17 (9.5)161 (81.5)
77
ER/PgR status at primaryBoth absentER absent, PgR >0ER> 0, PgR absentER>0 and PgR >0
52 (20.4)6 (2.3)
39 (15.3)158 (62.0)
HER2 status at primaryNot overexpressed OverexpressedUnknown
124 (69.6) 54 (30.4)
77
203 cases (79.6%) endocrine responsive tumor expressing ER and/or PgR
Characteristics of patient study populationN (%) Median (range)
Type of treatment received prior to liver biopsy*No treatmentOnly CTOnly HTOnly ITCT+HTCT+ITHT+ITCT+HT+ITUnknown
7 (3.0)54 (23.3)99 (42.7)
2 (0.9)59 (25.4)
3 (1.3)4 (1.7)4 (1.7)
7
Time from diagnosis to liver biopsy (years) 3.4 (0-18.3)
Number of metastatic sites at the time of liver biopsy12≥3
152 (60.6)60 (23.9)39 (15.5)
* 16 pts had liver synchronous mts and were not considered
Overall discordance rate (95% CI): 13.9% (9.1-20.1) * 83 pts with missing value at primary or at liver biopsy were not considered
p<0.001
Impact of the receptor status discordance on therapy choices
Overall, discordance in ER/PgR and/or HER2 status between primary and
liver metastases
Summary
• “In the era of continuing biological and therapeutic advances should we continue to use a historical pathological snapshot of the primary tumor or should we reassess biology of metastatic disease?”
Summary• In our study discordance for ER, PgR, and HER2
status between primary tumor and liver metastases was 14.5%, 48.6%, and 13.9% respectively, which led to a change of the therapy for 31 out of 255 pts (12.1%)
• The main limitation is related to the retrospective analysis
• Another limitation is related to the manual scoring of ER, PgR and HER2
Conclusions• There is emerging evidence that tumor
receptor status may change dynamically during the natural history of the disease
• When safe and easy to perform, a biopsy of the metastatic lesion should be considered in all patients, particularly when there is a long interval from the first diagnosis, since it is likely to impact treatment choice.
Acknowledgements :• Aron Goldhirsch• Giuseppe Curigliano• Giuseppe Viale• Luca Fumagalli• Vincenzo Bagnardi• Simona Giudici• Gaetano Aurilio• Paolo Della Vigna• Lorenzo Monfardini